A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa (P. Aeruginosa)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 10 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Colistimethate sodium (Primary)
Indications Bronchiectasis; Pseudomonal infections
Focus Registrational; Therapeutic Use
Acronyms PROMIS II
Sponsors Zambon SpA

Most Recent Events

12 Sep 2024 According to a Zambon SpA Media Release, results of this study were published in The Lancet Respiratory Medicine journal.
12 Sep 2024 Results presented in a Zambon SpA Media Release.
08 Feb 2024 This trial has been completed in Portugal (Global end date: 15 Mar 2022).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight